TGFB1 and Myocardial fibrosis: The use of p38 MAPK inhibitors reduces MAPK/TGFβ-1 expression in the myocardium of pressure-loaded mouse models, thereby inhibiting myocardial fibrosis and restoring cardiac function [46].